pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
412
stories
18d
Boticelli Foods Recalls Bettergoods Pistachio Nut Butter Because of Possible Health Risk
fda recalls
18d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
18d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
20d
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
21d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
21d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
21d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
21d
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
22d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
22d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
22d
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
endpoints
22d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
22d
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
22d
Sanofi records €1B+ write-off, ends work on two immunology assets
endpoints
22d
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
22d
Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one
fiercebiotech
22d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
22d
GSK pens $110M biological datasets pact with AI biotech Relation
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
22d
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
22d
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
23d
AbCellera, Vertex partner on next-gen T-cell engagers
biopharma dive
23d
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
23d
Do you need oncology experience to land an oncology job?
biospace
23d
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
23d
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
23d
Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera
fiercebiotech
← prev
page 4 of 14
next →
